Evaluation of the Effect of Benzonatate on QT Intervals Following Single Dose Administration of Benzonatate to Healthy Volunteers
Information source: Pfizer
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy Volunteers
Intervention: Benzonatate 200 mg (Drug); Benzonatate 800 mg (Drug); Moxifloxacin 400 mg (Drug); Placebo (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Pfizer Official(s) and/or principal investigator(s): Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer
Summary
The primary objective of this study is to determine the effects of benzonatate (200 mg and
800 mg) on the QT interval following single dose oral administration at each time point
post-dose.
Clinical Details
Official title: Evaluation of the Effect of Benzonatate on QT Intervals Following Single Dose Administration of Benzonatate to Healthy Volunteers
Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science
Primary outcome: Fridericia-corrected QTc change from the pre-dose time point to the post-dose time points following administration of study drug in therapeutic (200 mg) and supratherapeutic doses (800 mg).
Secondary outcome: QT interval for Benzonatate, 4-(butylamino)benzoic acid (BBA-major metabolite of benzonatate), and moxifloxacin.PR interval, QRS complex from single 12-lead electrocardiogram (ECG) Cmax (maximum plasma concentration) for BT and BBA measured in mcg/mL Tmax (time of maximum plasma concentration) for BT and BBA measured in minutes t½ (terminal half-life) for BT and BBA measured in minutes AUClast for BT and BBA measured in mcg•hr/mL AUCinf for BT and BBA measured in mcg•hr/mL Cmax(dn) for BT and BBA measured in mcg/mL AUClast(dn) for BT and BBA measured in mcg•hr/mL AUCinf(dn) for BT and BBA measured in mcg•hr/mL CL/F for BT measured in L/hr Vz/F for BT measured in L
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Healthy male and female subjects between the ages of 18 and 55 years, inclusive.
Healthy is defined as no clinically relevant abnormalities identified by a detailed
medical history, full physical examination, including blood pressure and pulse rate
measurement, 12- lead ECG and clinical laboratory tests.
- Female subjects of non-childbearing potential must meet at least one of the following
criteria:
1. Achieved postmenopausal status, defined as: cessation of regular menses for at
least 12 consecutive months with no alternative pathological or physiological
cause; and have a serum FSH level within the laboratory's reference range for
postmenopausal females;
2. Have undergone a documented hysterectomy and/or bilateral oophorectomy;
3. Have medically confirmed ovarian failure. All other female subjects (including
females with tubal ligations and females that do NOT have a documented
hysterectomy, bilateral oophorectomy and/or ovarian failure) will be considered
to be of childbearing potential.
- Body mass index (BMI) of 17. 5 to 30. 5 kg/m2, inclusive, and a total body weight >50
kg (110 lb).
- Evidence of a personally signed and dated informed consent document indicating that
the subject has been informed of all aspects of the study.
- Subjects willing and able to comply with scheduled visits, treatment plan, laboratory
tests, and other study procedures.
Exclusion Criteria:
- Significant ECG abnormality at screening as determined by the investigator.
- History or risk factors of QT prolongation or torsades de pointes, congenital
deafness and family history of sudden death.
- 12-lead ECG demonstrating QTcF >450 msec or a QRS interval >110 msec at Screening.
- Use of medications or dietary supplements capable of inducing or inhibiting hepatic
enzyme metabolism or transport (e. g., barbiturates, rifampin, carbamazepine,
phenytoin, primidone, or St. John's Wort) within 28 days of the first dose of study
medication.
- Consumption of grapefruit or grapefruit containing products within 7 days prior to
the first dose of study medication.
- Known history of hypersensitivity, allergy, severe adverse drug reaction or
intolerance to quinolone antibiotics.
- Known hypersensitivity to benzonatate or other ester-type local anesthetics (ie,
tetracaine, procaine).
- Subjects with a presence or history of dysphagia or difficulty swallowing pills.
- Subjects taking any concomitant anticonvulsant medications or with a history of
seizure disorder.
- Subjects with a positive response to the question of actual attempt in the suicidal
behavior section of the C-SSRS (Columbia-Suicide Severity Rating Scale). Subjects
with active suicidal ideation with intent to act within 6 months of screening as
determined by a positive response to questions 4 or 5 in the suicidal ideation
section of the C-SSRS.
- Screening laboratory values considered clinically significant by the investigator.
- Screening supine blood pressure ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic),
following at least 5 minutes of rest.
Locations and Contacts
Pfizer Investigational Site, Overland Park, Kansas 66212, United States
Additional Information
To obtain contact information for a study center near you, click here.
Starting date: May 2014
Last updated: July 31, 2014
|